Edition:
United Kingdom

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

53.60USD
3:54pm BST
Change (% chg)

$-0.10 (-0.19%)
Prev Close
$53.70
Open
$53.90
Day's High
$53.90
Day's Low
$52.00
Volume
32,750
Avg. Vol
223,620
52-wk High
$136.90
52-wk Low
$47.10

Select another date:

Fri, Jun 29 2018

Puma Biotech gets EU panel nod for breast cancer drug

Puma Biotechnology Inc  on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

Puma Biotech gets EU panel nod for breast cancer drug

June 29 Puma Biotechnology Inc on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

Puma Biotech says Europe likely to approve breast cancer drug

Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

Puma Biotech says Europe likely to approve breast cancer drug

Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

UPDATE 1-Puma Biotech says Europe likely to approve breast cancer drug

June 26 Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

Puma Biotech says Europe likely to approve breast cancer drug

June 26 Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

Former Puma Biotech exec gets U.S. prison term for insider trading

BOSTON, June 20 A former Puma Biotechnology Inc executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing.

BRIEF-Puma Biotechnology Q1 Loss Per Share $0.65

* PUMA BIOTECHNOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America

* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA

BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines

* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS

Select another date: